312 results on '"Glioblastomas -- Care and treatment"'
Search Results
52. Studies Conducted at Cleveland Clinic on One-Carbon Group Transferases Recently Reported (Correlation Between the Residual Tumor Volume, Extent of Tumor Resection, and O-6-Methylguanine DNA Methyltransferase Status in Patients with Glioblastoma)
53. New Glioblastomas Data Have Been Reported by Researchers at Department of Neurosurgery (Efficacy of D,L-methadone in the treatment of glioblastoma in vitro)
54. Antioxidant and anticancer activities of extract of Inula helenium (L.) in human U-87 MG glioblastoma cell line
55. Aivita Biomedical gets US FDA nod to begin phase II trial of ROOT OF CANCER technology in patients with glioblastoma multiforme
56. Research from German Cancer Research Center Yields New Findings on Biomarkers [Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation-the NCT Neuro Master Match (N2M2) ...]
57. Investigators from University of California Have Reported New Data on Glioblastomas (Tumor treating fields: a new approach to glioblastoma therapy)
58. Findings in the Area of Alkylating Agents Reported from Mayo Clinic (Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02)
59. Studies from University of Alexandria Further Understanding of Glioblastomas (Management of Glioblastoma Multiforme in a Patient Treated With Ketogenic Metabolic Therapy and Modified Standard of Care: A 24-Month Follow-Up)
60. New Glioblastomas Findings from Dana-Farber Cancer Institute Described (Phase 2 and Biomarker Study of Trebananib, an Angiopoietin-Blocking Peptibody, With and Without Bevacizumab for Patients With Recurrent Glioblastoma)
61. Findings from German Cancer Research Center Update Knowledge of Glioblastomas (Cell death-based treatment of glioblastoma)
62. Personalized Treatment of Glioblastoma Via Image-Guided Predictive Modeling of Recurrence: A Single-Arm, Single Institutional Pilot Prospective Study of Dose-Escalated Radiation Therapy
63. FDA grants Amgen glioblastoma treatment orphan status
64. Study Results from Tel Aviv Sourasky Medical Center in the Area of Glioblastomas Reported [Short delay in initiation of radiotherapy for patients with glioblastoma- effect of concurrent chemotherapy: a secondary analysis from the NRG ...]
65. Kazia granted orphan status for glioblastoma treatment
66. New Glioblastomas Data Have Been Reported by Researchers at Vanderbilt University (Utilization of hypofractionated radiotherapy in treatment of glioblastoma multiforme in elderly patients not receiving adjuvant chemoradiotherapy: A National ...)
67. New Cytokines Findings Reported from Central South University (Novel Therapy for Glioblastoma Multiforme by Restoring LRRC4 in Tumor Cells: LRRC4 Inhibits Tumor-Infitrating Regulatory T Cells by Cytokine and Programmed Cell Death 1-Containing ...)
68. Data on Glioblastomas Reported by C. Marosi and Co-Researchers (The course of quality of life and neurocognition in newly diagnosed patients with glioblastoma)
69. Enhanced antitumor effects of radiotherapy combined local nimustine delivery rendezvousing with oral temozolomide chemotherapy in glioblastoma patients
70. Plus Therapeutics Completes Sixth Dosing Cohort in ReSPECT Glioblastoma Trial
71. First Patient Enrolled in Novocures Global Phase 3 TRIDENT Trial of Optune Concurrent with Radiation Therapy in Newly Diagnosed Glioblastoma
72. First Patient Enrolled in Novocure's Global Phase 3 TRIDENT Trial of Optune[R] Concurrent with Radiation Therapy in Newly Diagnosed Glioblastoma
73. Medicenna Hosting Key Opinion Leader Call on MDNA55 for the Treatment of Recurrent Glioblastoma Multiforme
74. Medicenna Hosting Key Opinion Leader Call on MDNA55 for the Treatment of Recurrent Glioblastoma Multiforme
75. AIVITA Biomedical's Phase 2 Glioblastoma Trial Shows Improved Progression Free Survival
76. AIVITA Biomedical's Phase 2 Glioblastoma Trial Shows Improved Progression Free Survival
77. Plus Therapeutics Announces Initiation of Final Cohort of ReSPECT Glioblastoma Trial
78. Plus Therapeutics Announces Initiation of Final Cohort of ReSPECT(TM) Glioblastoma Trial
79. TRACON Announces FDA Orphan Drug Designation for TRC102 in Malignant Glioma, Including Glioblastoma
80. TRACON Announces FDA Orphan Drug Designation for TRC102 in Malignant Glioma, Including Glioblastoma
81. New Data Supports iCAD's Xoft Brain IORT as Feasible Treatment for Recurrent Glioblastoma
82. New Data Supports iCADs Xoft Brain IORT as Feasible Treatment for Recurrent Glioblastoma
83. New Data Supports iCAD's Xoft Brain IORT as Feasible Treatment for Recurrent Glioblastoma
84. ERC-USA Announces Expansion of Glioblastoma Right-to-Try Treatment for ERC1671 with NYU Winthrop Hospital
85. ERC-USA Announces Expansion of Glioblastoma Right-to-Try Treatment for ERC1671 with NYU Winthrop Hospital
86. BerGenBio ASA: BERGENBIO ANNOUNCES FIRST PATIENT DOSED IN RECURRENT GLIOBLASTOMA INVESTIGATOR SPONSORED PHASE I|II STUDY ASSESSING SELECTIVE AXL INHIBITOR BEMCENTINI
87. Bergenbio Announces First Patient Dosed in Recurrent Glioblastoma Investigator Sponsored Phase I|II Study Assessing Selective AXL Inhibitor Bemcentinib
88. Bergenbio Announces First Patient Dosed in Recurrent Glioblastoma Investigator Sponsored Phase I|II Study Assessing Selective AXL Inhibitor Bemcentinib
89. Ivy Brain Tumor Center and COVID Nurse, Ian Youngblood, Honor Second Annual National Glioblastoma Day on July 22, 2020
90. MediciNova Announces Positive Preclinical Results Regarding MN-166 (ibudilast) in Glioblastoma (GBM) Published in Frontiers in Immunology
91. MediciNova Announces Positive Preclinical Results Regarding MN-166 (ibudilast) in Glioblastoma (GBM) Published in Frontiers in Immunology
92. Ziopharm Oncology Completes Enrollment of Phase 2 Trial Evaluating Controlled IL-12 in Combination with Libtayo(R) in Patients with Glioblastoma
93. GMB RESPONDS TO TRANSPORT SELECT COMMITTEE REPORT INTo BRITISH AIRWAYS TREATMENT OF STAFF; The report has confirmed that British Airways are behaving in a deeply opportunistic way
94. Karyopharm Announces Dosing of First Patient in a Phase 1|2 Study of Selinexor in Combination with Standard of Care Therapy for Patients with Newly Diagnosed or Recurrent Glioblastoma
95. Karyopharm Announces Dosing of First Patient in a Phase 1/2 Study of Selinexor in Combination with Standard of Care Therapy for Patients with Newly Diagnosed or Recurrent Glioblastoma
96. NW Bio Provides Update On Projected Timing For Data Lock For Phase 3 Trial of DCVax-L for Glioblastoma Brain Cancer
97. NW Bio Provides Update On Projected Timing For Data Lock For Phase 3 Trial of DCVax(r)-L for Glioblastoma Brain Cancer
98. INOVIO's INO-5401 in Combination with PD-1 Inhibitor Libtayo (cemiplimab) Demonstrates 85% of Newly Diagnosed Glioblastoma Patients Are Alive 12 Months Following Treatment
99. INOVIO's INO-5401 in Combination with PD-1 Inhibitor Libtayo(R) (cemiplimab) Demonstrates 85% of Newly Diagnosed Glioblastoma Patients Are Alive 12 Months Following Treatment
100. China NMPA Approves Optune for the Treatment of Newly Diagnosed and Recurrent Glioblastoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.